News
Sarepta reports Third patient death
Digest more
Key Takeaways Sarepta Therapeutics shares were down nearly 25% early Friday morning.The tumble followed a report that a third ...
A third patient has died this year after getting a gene therapy from Sarepta Therapeutics Inc., raising questions about the ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback